Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Conditions

• Adenocarcinoma of the Lung

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Camrelizumab — DRUG
  Intravenous administration of (200mg/3weeks)
• Albumin Paclitacxel — DRUG
  intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
• Apatinib — DRUG
  Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)

Study Details

This study is a single arm, open label, national multicenter study, to explore the efficacy and safety of the combination of Camrelizumab, apatinib and albumin paclitaxel in advanced untreated EGFR Wild Type and ALK-negative Lung Adenocarcinoma. The study does not consider PD-L1 expression, but tumor samples need to be explored by PD-L1 detection and other exploratory analysis.

Key Dates

Start date

Aug 26, 2020

Status verified

Nov 2022

Primary completion

May 15, 2023

Completion

Jul 15, 2023

Study Design

Enrollment

63 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Camrelizumab combined with Albumin Paclitacxel and Apatinib.
  Participants are given intravenous administration of Camrelizumab (200mg/3w) in addition with intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles) and Apatinib (250mg Qd po for 5 days,, take rest for 2 days every week). Treatment terminates when disease progression, death or unacceptable toxicity.

Primary Outcome Measure

PFS [ Time Frame: Up to 24 months ]